Benzhydryl Compounds/economics; Cresols/economics; Mandelic Acids/economics; Phenylpropanolamine/economics; Quinuclidines/economics; Tetrahydroisoquinolines/economics; Urinary Bladder, Overactive/drug therapy; Urinary Bladder, Overactive/economics; Urinary Incontinence/economics; Benzhydryl Compounds/administration & dosage; Benzhydryl Compounds/adverse effects; Cohort Studies; Cost-Benefit Analysis; Cresols/administration & dosage; Cresols/adverse effects; Humans; Incontinence Pads/economics; Incontinence Pads/statistics & numerical data; Mandelic Acids/administration & dosage; Mandelic Acids/adverse effects; Markov Chains; Medication Adherence/statistics & numerical data; Models, Economic; Muscarinic Antagonists/administration & dosage; Muscarinic Antagonists/adverse effects; Muscarinic Antagonists/economics; Patient Dropouts/statistics & numerical data; Phenylpropanolamine/administration & dosage; Phenylpropanolamine/adverse effects; Quality-Adjusted Life Years; Quinuclidines/administration & dosage; Quinuclidines/adverse effects; Solifenacin Succinate; Tetrahydroisoquinolines/administration & dosage; Tetrahydroisoquinolines/adverse effects; Tolterodine Tartrate; Treatment Outcome; United Kingdom; Urinary Bladder, Overactive/complications; Urinary Incontinence/drug therapy; Urinary Incontinence/etiology